A Prospective, Open-Label, Multicenter Study Comparing Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Malignant melanoma; Rhabdomyosarcoma; Solid tumours
- Focus Diagnostic use
- Sponsors Cardinal Health; Navidea Biopharmaceuticals
- 27 Jun 2017 Status changed from active, no longer recruiting to recruiting.
- 02 May 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Apr 2017 Planned number of patients changed from 32 to 27.